Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
UK-based Mundipharma has agreed a deal worth up to $600 million to acquire exclusive Japanese rights for Invossa (TissueGene-C) with South Korean firm Kolon Life Science. 19 November 2018
UK-headquartered commercial-stage biotech firm Orchard Therapeutics today announced two additions to its global commercial leadership team, appointing Robin Kenselaar as senior vice president and general manager, EMEA commercial operations, and Brad Mathis as vice president, US commercial operations. 8 November 2018
When Per Falk, Ferring’s chief science officer, assumes the additional responsibility of becoming president of the executive committee on January 1 next year, he will be the envy of many big pharma leaders. 5 November 2018
Michel Pettigrew, the most senior officer at privately-held drugmaker Ferring, is to retire at the end of the year, the Switzerland-based company has announced. 31 October 2018
US biotech Celgene has appointed Dr Alise Reicin as president, global clinical development, reporting to Mark Alles, chairman and chief executive, effective November 1, 2018. 24 October 2018
Simon Jose, a Brit who has spent more than 30 years in pharma, is to become chief commercial officer of Idorsia, the research-based spin-out from Actelion following the latter’s acquisition by Johnson & Johnson. 23 October 2018
Swedish firm Medivir has announced that Uli Hacksell will replace Christine Lind as chief executive, with immediate effect, just 18 months after she took up the position. 16 October 2018
Jesper Brandgaard (pictured above) is to retire after 20 years with Danish pharma major Novo Nordisk, vacating the role of executive vice president, Biopharm and Legal Affairs. 15 October 2018
Incoming Pfizer chief executive Albert Bourla is to stamp his mark firmly on the company’s leadership, as the firm announced a new executive team ready to clock on from the commencement of his tenure next year. 10 October 2018
Ireland-headquartered generic and OTC drugmaker Perrigo, which recently said it was restructuring into two separate units, has announced the appointment of Murray Kessler as president, chief executive and member of the board of directors, effective immediately. 10 October 2018
The Mundipharma network of independent associated companies today confirmed the appointment of Philippe Bastide, who joins as head of biosimilars, Mint Commercial. 5 October 2018
Ian Read’s eight-year stint as chief executive of the world’s biggest pharma company will come to an end in three months time, when he will be replaced by current chief operating officer (COO), Albert Bourla. 1 October 2018
German pharma major Bayer has appointed Sebastian Guth as president of Pharmaceuticals, Americas Region, comprising the USA, Canada, Central and Latin America, effective December 1, 2018. 28 September 2018
Carri Duncan has left her role as senior investor relations manager with German pharma major Bayer to join the CAR-T specialist Celyad. 27 September 2018
Adam Keeney has been appointed president and chief executive of NodThera, a biotech focused on the discovery and development of NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. 24 September 2018
San Franciscan microbial genomics specialist uBiome has raised $83 million in a series C financing round directed at funding an expansion into therapeutics. 21 September 2018